adaura: osimertinib adjuvant therapy in egfr mutated nsclc
Published 3 years ago • 124 plays • Length 2:33Download video MP4
Download video MP3
Similar videos
-
3:52
is adjuvant chemotherapy in egfr mutated nsclc still required?
-
3:30
adaura: osimertinib adjuvant therapy on cns disease recurrence
-
6:20
asco 2023 highlights on adjuvant osimertinib in resected egfr mutated nsclc: the adaura trial
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
1:42
adaura: the benefit of adjuvant osimertinib
-
6:30
osimertinib adjuvant therapy in patients with early stage egfr mutated nsclc after tumour resection
-
2:12
esmo 2020 highlights on adjuvant osimertinib for egfr mutated nsclc: the adaura study
-
2:13
overall-survival analysis of adaura: osimertinib in resected egfrm stage ib-iiia nsclc
-
4:25
adaura: osimertinib as adjuvant therapy in stage iii egfr nsclc
-
8:06
adaura: osimertinib post-tumor resection in nsclc
-
3:19
adjuvant osimertinib in resected egfr-mutated nsclc
-
3:13
updates from adaura: continued dfs benefit with osimertinib vs. placebo
-
1:35
dr. herbst on the benefit of adjuvant osimertinib in egfr-mutant nsclc
-
4:24
reflections on the adaura study
-
1:04
molecular testing in egfr mutant driven nsclc
-
5:03
adaura results: adjuvant osimertinib for egfrm non-small cell lung cancer
-
0:58
adaura study demonstrates promising efficacy for osimertinib in egfr-mutant nsclc
-
2:20
adjuvant osimertinib in resected egfrm nsclc: the os data from the adaura trial
-
2:03
amivantamab and lazertinib in treatment-naïve egfr-mutant nsclc